Shibuya, Hitoshi
Hijioka, Susumu
Sakamoto, Yasunari
Ito, Tetsuhide
Ueda, Keijiro
Komoto, Izumi
Kobayashi, Noritoshi
Kudo, Atsushi
Yasuda, Hiroaki
Miyake, Hayato
Arita, Junichi
Kiritani, Sho
Ikeda, Masafumi
Imaoka, Hiroshi
Ueno, Makoto
Kobayashi, Satoshi
Furuta, Mitsuhiro
Nagashio, Yoshikuni
Murohisa, Gou
Aoki, Taku
Matsumoto, Shigemi
Motoya, Masayo
Azemoto, Nobuaki
Itakura, Jun
Horiguchi, Shigeru
Yogi, Tatsuji
Kawagoe, Tetsuro
Miyaoka, Youichi
Imamura, Fumito
Senju, Michio
Arioka, Hitoshi
Hara, Kazuo
Imamura, Masayuki
Okusaka, Takuji
Article History
Received: 30 May 2018
Accepted: 23 July 2018
First Online: 27 July 2018
Compliance with ethical standards
:
: Author Masafumi Ikeda has received research grants from Ono Pharmaceutical, AstraZeneca, Taiho Pharmaceutical, Merck Serono, Yakult, Kyowa Hakko Kirin, Eisai, Eli Lilly Japan, Baxter, ASLAN Pharmaceuticals, Chugai Pharmaceutical; speaker honoraria from Bayer Yakuhin, Taiho Pharmaceutical, Novartis Pharma, Bristol-Myers Squibb, Eli Lilly Japan. Author Susumu Hijioka has received speaker honoraria from Novelpharma, Novartis Pharma and Teijin Pharma. Author Hiroshi Imaoka has received a speaker honorarium from Novartis Pharma. The other authors have no conflicts of interest to declare.
: All procedures involving human participants proceeded in accordance with the ethical standards of each institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Formal consent is not required for this type of study.
: Informed consent was obtained from all individual participants included in the study.